Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia
Authors:
- 1 August 2019
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 38 (8) , 860-865
Abstract
Background: Finnish studies have shown a significant impact of 10-valent pneumococcal conjugate vaccine (PCV10) on nonnotified clinically suspected invasive pneumococcal disease (IPD). We used a similar vaccine probe design to estimate PCV7 and PCV13 impact in Australian children. Methods: Season and age-matched pre-PCV7 cohorts (born in 2002–2004) were compared with PCV7-early and PCV7-late, and PCV13-eligible cohorts. Using linked notification and hospitalization data, we calculated relative rate reductions (RRRs) and absolute rate reductions (ARRs) for notified IPD, and nonnotified clinically suspected IPD or unspecified sepsis (first hospitalization with an International Classification of Diseases 10th Revision-Australian Modification code: A40.3/G00.1/M00.1 or A40.9/A41.9/A49.9/G00/I30.1/M00, respectively). Results: Significant reductions in all outcomes were observed comparing PCV7-early and PCV7-late and PCV13-eligible to pre-PCV7 cohorts. RRRs were high for both notified and nonnotified clinically suspected IPD (range 71%–91%), but ARRs were lower for nonnotified (5–6/100,000 person-years) than for notified cases (59–70/100,000 person-years). RRRs for the combined outcome of nonnotified clinically suspected IPD or unspecified sepsis were lower at 21%–24% for PCV7-eligible cohorts and 36% for the PCV13-eligible cohort, but ARRs were considerable due to the high pre-PCV7 rates (ARR 37-31/100,000 person-years for PCV7-early and PCV7-late cohorts and 54/100,000 person-years for PCV13). Conclusions: This study provides a quantitative estimate of the total burden of IPD preventable by PCV7 and PCV13 vaccination programs in Australia. ARRs (compared with prevaccination) were significant but smaller than in Finland (122/100,000 for the combined outcome) and longer-term follow-up is required to determine the additional impact of PCV13 above that seen for PCV7. Country-specific studies are needed to accurately estimate the burden of pneumococcal disease preventable by vaccination and cost-effectiveness of PCV vaccination programs.Keywords
This publication has 10 references indexed in Scilit:
- Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in AustraliaVaccine, 2018
- Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite controlBMC Medicine, 2018
- Probabilistic linkage of national immunisation and state-based health records for a cohort of 1.9 million births to evaluate Australia’s childhood immunisation programInternational Journal of Population Data Science, 2017
- Long-term Impact of a “3 + 0” Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002–2014Clinical Infectious Diseases, 2016
- Establishing a process for conducting cross‐jurisdictional record linkage in AustraliaAustralian and New Zealand Journal of Public Health, 2016
- Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal DiseasePediatrics, 2015
- Long term population impact of seven-valent pneumococcal conjugate vaccine with a “3+0″ schedule—How do “2+1″ and “3+1″ schedules compare?Vaccine, 2015
- Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trialThe Lancet Respiratory Medicine, 2014
- Use of vaccines as probes to define disease burdenThe Lancet, 2014
- The Changing Epidemiology of Invasive Pneumococcal Disease in Aboriginal and Non‐Aboriginal Western Australians from 1997 through 2007 and Emergence of Nonvaccine SerotypesClinical Infectious Diseases, 2010